Albert J Farias1,2, India J Ornelas3, Sarah D Hohl4, Steven B Zeliadt3,5, Ryan N Hansen6, Christopher I Li4,7, Beti Thompson3,4. 1. Department of Health Services, University of Washington, Seattle, WA, USA. albert.j.farias@uth.tmc.edu. 2. School of Public Health, Department of Epidemiology and Human Genetics, University of Texas Health Sciences Center Houston, 1200 Pressler St., Suite E633, Houston, TX, 77035, USA. albert.j.farias@uth.tmc.edu. 3. Department of Health Services, University of Washington, Seattle, WA, USA. 4. Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Seattle, WA, USA. 5. Department of Veterans Affairs Puget Sound Health Care System, Health Services Research and Development Center of Excellence, Seattle, WA, USA. 6. Department of Pharmacy, University of Washington, Seattle, WA, USA. 7. University of Washington, Department of Epidemiology, Seattle, WA, USA.
Abstract
PURPOSE: To better understand how physicians communicate with breast cancer patients about adjuvant endocrine therapy (AET), we explored, from the breast cancer patient's perspective, dimensions of the patient-provider communication among women who were on active AET treatment. METHODS: Qualitative methods using semi-structured in-depth interviews were conducted with breast cancer patients (n = 22) who filled a prescription for AET in the previous 12 months. Interview questions aimed to elicit experiences with AET. We reviewed and coded interview transcripts using qualitative principles of inductive reasoning to identify concepts and themes from interview data. RESULTS: We grouped emergent themes into four major functions of physician-patient communication: (1) information exchange, (2) decision-making to take and continue AET, (3) enabling patient self-management and monitoring potential side effects, and (4) emotional support. Physicians exchanged information with patients in a way that they understood and enhanced patient's health literacy regarding the benefits and knowledge of AET. Physicians empowered patients to make decisions about their care. Patients expressed trust and confidence in their physician which helped them seek care when needed. Patients reported a high degree of self-efficacy to self-manage AET and were continuing treatment despite potential side effects. CONCLUSIONS: The results from our study suggest that women's interactions and communication with their physician may be an important factor that contributes to the continued use of AET. Physicians who can communicate information about AET treatment benefits, purpose, and expectations in a way that patients can understand is a critical aspect of care that needs to be further studied.
PURPOSE: To better understand how physicians communicate with breast cancerpatients about adjuvant endocrine therapy (AET), we explored, from the breast cancerpatient's perspective, dimensions of the patient-provider communication among women who were on active AET treatment. METHODS: Qualitative methods using semi-structured in-depth interviews were conducted with breast cancerpatients (n = 22) who filled a prescription for AET in the previous 12 months. Interview questions aimed to elicit experiences with AET. We reviewed and coded interview transcripts using qualitative principles of inductive reasoning to identify concepts and themes from interview data. RESULTS: We grouped emergent themes into four major functions of physician-patient communication: (1) information exchange, (2) decision-making to take and continue AET, (3) enabling patient self-management and monitoring potential side effects, and (4) emotional support. Physicians exchanged information with patients in a way that they understood and enhanced patient's health literacy regarding the benefits and knowledge of AET. Physicians empowered patients to make decisions about their care. Patients expressed trust and confidence in their physician which helped them seek care when needed. Patients reported a high degree of self-efficacy to self-manage AET and were continuing treatment despite potential side effects. CONCLUSIONS: The results from our study suggest that women's interactions and communication with their physician may be an important factor that contributes to the continued use of AET. Physicians who can communicate information about AET treatment benefits, purpose, and expectations in a way that patients can understand is a critical aspect of care that needs to be further studied.
Authors: Hans Wouters; Anne M Stiggelbout; Marcel L Bouvy; Gemma A Maatman; Erica C G Van Geffen; Robbert Vree; Johan W Nortier; Liset Van Dijk Journal: Clin Breast Cancer Date: 2014-06-02 Impact factor: 3.225
Authors: Alan J Christensen; M Bryant Howren; Stephen L Hillis; Peter Kaboli; Barry L Carter; Jamie A Cvengros; Kenneth A Wallston; Gary E Rosenthal Journal: J Gen Intern Med Date: 2010-02-20 Impact factor: 5.128
Authors: Dan O'Hair; Melinda M Villagran; Elaine Wittenberg; Kenneth Brown; Monica Ferguson; Harry T Hall; Timothy Doty Journal: Health Commun Date: 2003
Authors: Lee S Schwartzberg; Patrick Cobb; Frank Senecal; David Henry; Kimary Kulig; Mark S Walker; Arthur C Houts; Edward J Stepanski Journal: Breast Date: 2009-04-01 Impact factor: 4.380
Authors: Dean Schillinger; John Piette; Kevin Grumbach; Frances Wang; Clifford Wilson; Carolyn Daher; Krishelle Leong-Grotz; Cesar Castro; Andrew B Bindman Journal: Arch Intern Med Date: 2003-01-13
Authors: C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto Journal: Lancet Date: 2011-07-28 Impact factor: 79.321
Authors: Jorge Muriel Fernandez; María José Sánchez Ledesma; Manuel López Millan; María Begoña García Cenador Journal: J Med Syst Date: 2017-03-27 Impact factor: 4.460
Authors: Felisa A Gonzales; Meera Sangaramoorthy; Laura A Dwyer; Salma Shariff-Marco; Amani M Allen; Allison W Kurian; Juan Yang; Michelle M Langer; Laura Allen; Bryce B Reeve; Stephen H Taplin; Scarlett Lin Gomez Journal: J Cancer Surviv Date: 2019-10-23 Impact factor: 4.442
Authors: Elizabeth Palmer Kelly; Julia McGee; Samilia Obeng-Gyasi; Chelsea Herbert; Rosevine Azap; Alizeh Abbas; Timothy M Pawlik Journal: Support Care Cancer Date: 2021-07-01 Impact factor: 3.603
Authors: Christine M Gunn; Michael K Paasche-Orlow; Sharon Bak; Na Wang; Jennifer Pamphile; Kerrie Nelson; Samantha Morton; Tracy A Battaglia Journal: JCO Oncol Pract Date: 2020-03-27
Authors: Kirsti I Toivonen; Devesh Oberoi; Kathryn King-Shier; Katherine-Ann L Piedalue; Joshua A Rash; Linda E Carlson; Tavis S Campbell Journal: Curr Oncol Date: 2021-07-05 Impact factor: 3.677